Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.43 |
| ▸ | VEGFA | P15692 | 3/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257797 | 0.88 | HSP90AA1 (0.41) | EGLN1VEGFAFLT1EGLN3HSP90AA1 | |
| SCHEMBL24257463 | 0.85 | EGLN1 (0.41) | EGLN1VEGFAFLT1EGLN3 | |
| Formic Acid SCHEMBL30452437 | 0.82 | EGLN1 (0.39) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL26259993 | 0.81 | EGLN1 (0.41) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL24257610 | 0.81 | EGLN1 (0.51) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL30453229 | 0.81 | EGLN1 (0.51) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL26259694 | 0.80 | EGLN1 (0.55) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL24257473 | 0.79 | EGLN1 (0.48) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL24257554 | 0.79 | EGLN1 (0.48) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL24257525 | 0.79 | EGLN1 (0.53) | EGLN1VEGFAFLT1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885VEGFA 1862/4885FLT1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.